Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935976 | 0.93 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL6936597 | 0.89 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL20402814 | 0.87 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL16702631 | 0.85 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1KDRSLC5A7MAOB | |
| SCHEMBL18123498 | 0.85 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL16702647 | 0.84 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL6936022 | 0.84 | HSP90AA1 (0.91) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL12968043 | 0.83 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL1607463 | 0.82 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1MAPK14LCKSRC | |
| SCHEMBL16702307 | 0.82 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1MAPK14LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885MAOA 4780/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | HSP90AA1 17/4885HSP90AB1 13/4885MAOA 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.